Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05731544 · ClinicalTrials.gov registry record · Phase 1
Study of BMF-219 in Healthy Adult Subjects and in Adult Subjects With Type 2 Diabetes Mellitus (T2D)
A Phase 1 study, sponsored by Biomea Fusion.
- Completed
- Registry status
- Phase 1
- Development phase
- 443
- Enrollment target
NCT05731544: Completed Phase 1 study, sponsored by Biomea Fusion.
NCT05731544 is a Phase 1 study that has completed, run by Biomea Fusion. The registered enrollment target is 443 participants, above the 60-participant average among 29,502 other Phase 1 trials with a reported enrollment target (638% higher). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT05731544, a Phase 1 study, has completed, sponsored by Biomea Fusion.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 443 participants
- Enrollment target
Study Summary
A Phase 1/ 2 Randomized, Double-Blind, Placebo-Controlled Single and Multiple Ascending Dose Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of BMF-219, an Oral Covalent Menin Inhibitor, in Healthy Adult Subjects and in Adult Subjects with Type 2 Diabetes Mellitus.
Primary Outcome
Assessed by treatment emergent adverse events. (TEAEs), drug discontinuation due to TEAEs, serious adverse events, clinically significant laboratory, vital, and ECG evaluations.
Interventions
- DRUG BMF-219
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 443 participants |
| Start Date | 2022-08-17 |
| Est. Completion | 2025-07-08 |
| Phase | Phase 1 |
What the finished NCT05731544 record still lists
NCT05731544 is an interventional study that assigns participants to a tested intervention. The registered 443 participants enrollment target is mid-sized for trials with a published cap, above the 60-participant average among 29,502 other Phase 1 trials with a reported enrollment target (638% higher).
The record links to 0 conditions, and to 1 intervention - of which BMF-219 is the first listed.
NCT05731544 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT05731544 about?
NCT05731544 is a clinical study titled "Study of BMF-219 in Healthy Adult Subjects and in Adult Subjects With Type 2 Diabetes Mellitus (T2D)". A Phase 1/ 2 Randomized, Double-Blind, Placebo-Controlled Single and Multiple Ascending Dose Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of BMF-219, an Oral Covalent Menin Inhibitor, in Healthy Adult Subjects and in Adult Subjects with Type 2 Diabetes Mellitus.
What is the current status of trial NCT05731544?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 443 participants. The study started on 2022-08-17. Estimated completion is 2025-07-08.
What interventions are being tested in trial NCT05731544?
The interventions under investigation include: BMF-219 (DRUG).
Who is sponsoring clinical trial NCT05731544?
This trial is sponsored by Biomea Fusion, which has 9 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT05731544's enrollment target sits among peer trials
443 59th of 2000 higher than 1,942 of 2,000 other Phase 1 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 1 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT06780670 · 443 participants · Phase 2
Open-label Study Comparing AAA817 Versus Standard of Care in the Treatment of Previously Treated PSMA-positive mCRPC Adults Who Have Disease Progressed on or After [177Lu]Lu-PSMA Targeted Therapy
- NCT06348394 · 444 participants · NA
Intracardiac Versus Transesophageal Echocardiographic Guidance for Left Atrial Appendage Occlusion
- NCT06700343 · 444 participants · Phase 3
Comparison Between ABP 692 and Ocrevus® (Ocrelizumab)
- NCT03704766 · 442 participants · NA
Alpha-Defensin and Synovial Proteins to Improve Detection of Pediatric Septic Arthritis
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI